ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.


Visit bctech for more information about ESSA Pharma.